RAS-RAF pathway mutations have been identified in 40–50% of ND patients while tumour protein p53 (TP53) mutations are present in 5% to 6% of ND and between 21% to 26% in relapsed and/or refractory (RR) MM patients [2,3,4,6,7,8]. This evidence concerns the gene TP53 and Miyoshi myopathy.